Vogenx Inc · NASDAQ:VOGX
Vogenx — Investor Presentation (October 2026)
22 slides from Vogenx's investor presentation, October 2026
Slide 1: Investor Presentation
Inve sto r P re s e ntation Phase 2b Clinical Stage Company Post Bariatric Hypoglycemia & Gastroparesis
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as “may,” “might,” “will,”
Slide 3: Corporate Overview
Corporate Overview METABOLIC & GASTROINTESTINAL Two indications with potential multi-billion-dollar addressable markets Post Bariatric Hypoglycemia (PBH) Gastroparesis No FDA-approved therapeutics One FDA-approved option exists; boxed warning Two successful Phase 2 studies completed; Phase 2b EMERGE
Slide 4: Leadership & Scientific Advisors
Leadership & Scientific Advisors Independent Directors Ken Toombs Former CEO at PA Consulting Peter Pieraccini Former CEO at ZenBio James Green, MBA Bill Wilkison, Ph. D. Steve Delmar Tim Boris, Esq. CEO CSO CFO Former General Counsel for Elucida Oncology TBD Search ongoing Scientific Advisors David
Slide 5: Pipeline
Pipeline Program Indication Pre-Clinical Phase 1 Phase 2a Phase 2b Phase 3 Post Bariatric Hypoglycemia (PBH) EMERGE Trial (Initiated Oct 2026) Mizagliflozin Gastroparesis (Phase 2 Initiate 1H27) SGLT-1 Inhibitor GIP-dependent Cushing’s Syndrome VGX-2857 Weight Maintenance VOGENX | INVESTOR PRESENTAT
Slide 6: Mizagliflozin Overview
Mizagliflozin Overview Novel Orally Dosed Small Molecule Inhibitor • Target: SGLT-1 locally in small intestine (gut restricted) • Mechanism of Action: Inhibition of glucose absorption and reductions in secretion of GIP and insulin Safety • Observed to be well tolerated in Phase 2 studies • No drug-r
Slide 7: Post Bariatric Hypoglycemic (PBH)
Post Bariatric Hypoglycemic (PBH) Indication Summary Prevalence (U.S.) ✓ Chronic disorder related to bariatric surgery, ~3 million characterized by reactive postprandial living bariatric surgery patients (+~200K surgeries/yr) hyperinsulinemic hypoglycemia HIDDEN SEGMENT ✓ Spectrum disease with varyi
Slide 8: PBH – Competitive Landscape
PBH – Competitive Landscape Reduce Development Reduce Reduce Insulin Company Product Candidate Drug Substance Target Mechanism Target Distribution Administration Glucose Status GIP Secretion Absorption Mizagliflozin Small Molecule SGLT-1 Inhibitor Gut Restricted Phase 2b Oral Amylyx Avexitide
Slide 9: PBH – Competitive Landscape
PBH – Competitive Landscape Safety & Tolerability ✓ Other drugs in development focus only on downstream effects that can lead to postprandial hyperglycemia (pathway to diabetes) ✓ Systemic injectable peptides with unknown long-term safety risks vs. mizagliflozin, a non-absorbable inhibitor ✓ A GLP-1
Slide 10: Post Bariatric Hypoglycemia (PBH)
POST BARIATRIC HYPOGLYCEMIA (PBH) The ideal PBH treatment would delay and reduce Therapeutics aimed only at reducing insulin secretion postprandial absorption of glucose and GIP secretion, without a reduction in glucose absorption may lead to thereby reducing the uncontrolled spike in insulin compli
Slide 11: PBH Mechanism: Upstream vs. Downstream
PBH Mechanism: Upstream vs. Downstream PBH Patient Increased SGLT-1 transporter expression in gut lumen Miza Inhibits Upstream Glucose Absorption X Miza Reduces GIP Excessive GIP secretion by Excessive GLP-1 secretion Production K cells by L cells T GLP-1 Antagonists Disrupts Downstream Binding Miza
Slide 12: Mizagliflozin for PBH Clinical Data
Mizagliflozin for PBH Clinical Data 12
Slide 13: Phase 2 Repeat Dose Study 012 for PBH
Phase 2 Repeat Dose Study 012 for PBH Study Objective: Confirm doses and regimen for Phase 2b Randomized, placebo-controlled, crossover, single-blind, repeat dose study Note: No run-in period 15 Enrolled What was tested? • 5 cohort X 3 subjects • Each cohort has placebo, MMTT Washout low dose and hi
Slide 14: Phase 2 Repeat Dose Study 012 for PBH
Phase 2 Repeat Dose Study 012 for PBH Change in Hypoglycemic Events Dose Reduction of L2 (SE) p-value Reduction of L3 (SE) p-value Mizagliflozin (012) 5 mg TID -0.35 (0.38) 0.61 -1.83 (0.60) 0.028 Mizagliflozin (012) 10 mg TID -1.47 (1.44) 0.50 -2 (0.58) 0.07 All Subjects dosed with either 5 mg (n=6
Slide 15: Phase 2 Repeat Dose Study 012 for PBH
Phase 2 Repeat Dose Study 012 for PBH Pharmacodynamics Reductions in Peak Insulin Reductions in Peak Glucose Improvement in Glucose Nadir Peak Insulin Mean Standard Glucose Peak Mean Standard Glucose Nadir Mean Standard Dose Dose Dose Change from Placebo Error Change from Placebo Error Change from P
Slide 16: Reductions in Postprandial Circulating GIP
Reductions in Postprandial Circulating GIP Reductions in GIP Across Patient Populations S ub ject Po p ulatio n Treatm ent G IP Red uctio n as % o f C o ntro l H ealthy S ub jects 5 m g TID (14 d ay) 79.0% Typ e 2 D iab etics 5 m g BID (6 d ay) 59.0% PBH Patients 5 m g (sing le d o se) 45.2% • Postp
Slide 17: Mizagliflozin for PBH – Clinical Development Plan
Mizagliflozin for PBH – Clinical Development Plan Phase 2b – EMERGE Study Placebo (n =12) Primary Endpoint: 21-Day Randomization 5 mg Miza TID MMTT Run-In Baseline MMTT (n =12) PK Time Course Composite change Level 2 (SMBG) and Level 3 (adjudicated) hypoglycemic events 10 mg Miza TID (n =12) 28 days
Slide 18: Mizagliflozin for Gastroparesis
Mizagliflozin for Gastroparesis 18
Slide 19: Gastroparesis - Overview
Gastroparesis - Overview • Gastroparesis (aka delayed gastric emptying or stomach paralysis) is a disorder that slows or stops the digestive process and disrupts normal bowel movement activity • Gastroparesis can be a chronic health problem with no effective long-term treatment Gastroparesis (Delaye
Slide 20: Mizagliflozin for Gastroparesis - Rationale
Mizagliflozin for Gastroparesis - Rationale Each core feature of gastroparesis is matched by a demonstrated effect of mizagliflozin GASTROPARESIS IS ASSOCIATED WITH MIZAGLIFLOZIN HAS BEEN SHOWN TO EXPECTED IMPACT Incretin Elevated fasting and postprandial GIP Reduce postprandial circulating GIP Norm
Slide 21: Mizagliflozin for Gastroparesis
Mizagliflozin for Gastroparesis Phase 2 POC Study Design Randomized, parallel group, double-blind, placebo-controlled study Placebo Randomization 28-Day 1:1:1 GEBT Run-In Baseline gastric Dose 1 ANMS GSCI-DD emptying time Dose 2 28 days treatment Phase 2 POC Study ➢ Randomized, double-blind, placebo
Slide 22: Vogenx
Vogenx